The PI3K/Akt pathway as a target in the treatment of hematologic malignancies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 550-559

  Kawauchi, Kiyotaka ^a,c   Ogasawara, Toshie ^a   Yasuyama, Masako ^a   Otsuka, Kuniaki ^a   Yamada, Osamu ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Akt; Hematologic malignancies; Molecular targeting therapy; PI3K

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; A 443654; ARSENIC TRIOXIDE; BAG 956; BAX 320; CELECOXIB; DEFOROLIMUS; EVEROLIMUS; GDC 0941; GSK 690693; IC 486068; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NPV BEX 235; NPV BEZ 235; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PWT 458; PX 866; QLT 394; RAPAMYCIN; SF 1126; TEMSIROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER INHIBITION; CANCER RELAPSE; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG BINDING; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCEMIA; IC 50; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; LYMPHADENOPATHY; LYMPHOMA; MANTLE CELL LLYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL LEUKEMIA; NEUTROPENIA; NONHUMAN; PROLYMPHOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; T CELL PROLYMPHOCYTIC LEUKEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

EID: 67651112149     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788451851     Document Type: Review

References (111)

1. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441(25), 424-430.
2. Martelli, A.M.; Tabellini, G.; Bortul, R.; Tazzari, P.L.; Cappellini, A.; Billi, A.M.; Cocco, L. Involvement of the phosphoinositide 3-kinase/ Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol. Histopathol., 2005, 20(1), 239-252.
3. Granville, C.A.; Memmott, R.M.; Gills, J.J.; Dennis, P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/ mammalian target of rapamycin pathway. Clin. Cancer Res., 2006, 12(3), 679-689.
4. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Update, 2008, 11(1-2), 32-50.
5. Amaravadi, R.; Thompson, C.B. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest., 2005, 115(10), 2618-2624.
6. Vanhaesebroeck, B.; Leevers, S.J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P.C.; Woscholski, R.; Parker, P.J.; Waterfield, M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem., 2001, 70, 535-602.
7. Knight, Z.A.; Chiang, G.G.; Alaimo, P.J.; Kenski, D.M.; Ho, C.B.; Coan, K.; Abraham, R.T.; Shokat, K.M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem., 2004, 12(17), 4749-4759.
8. Geng, L.; Tan, J.; Himmelfarb, E.; Schueneman, A.; Niermann, K.; Fu, A.; Cuneo, K.; Kesicki, E.A.; Treiberg, J.; Hayflick, J.S.; Hallahan, D.E. A specific antagonist of the p110?? catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res., 2004, 64(15), 4893-4899.
9. Billottet, C.; Grandage, V.L.; Gale, R.E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A.A selective inhibitor of the p110?? isoform of PI-3 kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene, 2006, 25(50), 6648-6659.
10. Yu, K.; Lucas, J.; Zhu, T.; Zask, A.; Gaydos, C.; Toral-Barza, L.; Gu, J.; Li, F.; Chaudhary, I.; Cai, P.; Lotvin, J.; Petersen, R.; Ruppen, M.; Fawzi, M.; Aryal-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Frost, P.; Gibbons, J. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther., 2005, 4(5), 538-545.
11. Ihle, N.T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M.I.; Paine-Murrieta, G.; Minion, D.J.; Halter, R.J.; Wipf, P.; Abraham, R.; Kirkpatrick, L,; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther., 2004, 3(7), 763-772.
12. Howes, A.L.; Chiang, G.G.; Lang, E.S.; Ho, C.B.; Powis, G.; Vuori, K.; Abraham, R.T.The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther., 2007, 6(9), 2505-2514.
13. Garlich, J.R.; De, P.; Dey N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H-K.; Peng, Q.; Durden, D.L. A vascular targeted pan phosphoinisitide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68(1), 206-215.
14. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitor. Bioorg. Med. Chem., 2006, 14(20), 6847-6858.
15. Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; Brandon, A.H.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67(12), 5840-5850.
16. Prevo, R.; Deutsch, E.; Sampson, O.; Diplexcito, J.; Cengel, K.; Harper, J.; O'Neill, P.; McKenna, W.G.; Patel, S.; Bernhard, E.J. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res., 2008, 68(14), 5915-593.
17. Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27(41), 5511-5526.
18. Maira, S-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7(7), 1851-1863.
19. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci., 2008, 99(9), 1734-1740.
20. Fujiwara, H.; Matsunaga, K.; Saito, M.; Hagiya, S.; Frukawa-K-I., Nakamura, H.; Ohizumi, Y. Halenaquinone, a novel phosphatidylinositol 3-kinase inhibitor from a marine sponge, induces apoptosis in PC12 cells. Eur. J. Pharm., 2001, 413, 37-45.
21. Aribiser, J.L.; Kau, T.; Konar, M.; Narra, K.; Ramchandran, R.; Summers, S.A.; Vlahos, C.J.; Ye, K.; Perry, B.N.; Matter, W.; Fischl, A.; Cook, J.; Silver, P.A.; Bain, J.; Cohen, P.; Whitmire, D.; Furness, S.; Govindarajan, B.; Bowen, J.P. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phoaphatidylinositol 3-kinase signaling and angiogenesis. Blood, 2007, 109(2), 560-565.
22. Shishodia, S.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem. Pharmacol., 2007, 74(1), 118-130.
23. Kawamata, N.; Chen, J.; Koeffler, H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood, 2007, 110(7), 2667-2673.
24. Feldman, R.I.; Wu, J.M.; Polokoff, M.A.; Kochanny, M.J.; Dinter, H.; Zhu, D.; Biroc, S.L.; Alicke, B.; Bryant, J.; Yuan, S.; Buckman, B.O.; Lentz, D.; Ferrer, M.; Whitlow, M.; Adler, M.; Finster, S.; Chang, Z.; Arnaiz, O. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem., 2005, 280(20), 19867-19874.
25. Stauffer, F.; Maira, S-M.; Furet, P.; Garcia-Echeverria, C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett., 2008, 18(3), 1027-1030.
26. Weisberg, E.; Banerji, L.; Wright, R.D.; Barrett, R.; Ray, A.; Moreno, D.; Catley, L.; Jiang, J.; Hall-Meyers, E.; Sauveur-Michel, M.; Stone, R.; Galinsky, I.; Fox, E.; Kung, A.L.; Griffin, J.D. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood, 2008, 111(7), 3723-3734.
27. Sato, S.; Fujita, N.; Tsuruo, T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene, 2002, 21(11), 1727-1738.
28. Zhu, J.; Huang, J.W.; Tseng, P.H.; Yang, Y-T.; Fowble, J.; Shiau, C-W.; Shaw, Y-J.; Kulp, S.K.; Chen, C-S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res., 2004, 64(12), 4309-4318.
29. Tseng, P.H.; Lin, H.P.; Zhu, J.; Chen, K-F.; Hade, E.M.; Young, D,C,; Byrd, J.C.; Grever, M.; Johnson, K.; Druker, B.J.; Chen, C-S. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood, 2005, 105(10), 4021-4027.
30. Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2(11), 1093-1103.
31. Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; van Blitterswijk, W.J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs, 2003, 14(2), 167-173.
32. Papa, V.; Tazarri, P.L.; Chiarini, F.; Cappellini, A.; Ricci, F.; Billi, A.M.; Evangelisti, C.; Ottaviani, E.; Martinelli, G.; Testoni, N.; McCubrey, J.A.; Martelli, A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22(1), 147-160.
33. Crul, M.; Rosing, H.; de Klerk, G.J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N.G.; Schellens, J.H.; Beijnen.; J.H.; ten Bokkel, Huinink, W.W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer, 2002, 38(12), 1615-1621.
34. Van Ummerson, L.; Binger, K.; Volkman, J.; Marnocha, R.; Tutsch, K.; Kolesar, J.; Arzoomanian, R.; Alberti, D.; Wilding, G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res., 2004, 10(22), 7450-7456.
35. Meuillet, E.J.; Mahadevan, D.; Vankayalapati, H.; Berggren, M.; Williams, R.; Coon, A.; Kozikowski, A.P.; Powis, G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl-myo-inositol analogues. Mol. Cancer Ther., 2003, 2(4), 389-399.
36. Gills, J.J.; Holbeck, S.; Hollingshead, M.; Hewitt, S,M,; Kozikowski, A.P.; Dennis, P.A. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther., 2006, 5(3), 713-722.
37. Barnett, S.F.; Defeo-Jones, D.; Fu, S.; Hancock, P.J.; Haskell, K.M.; Jones, R.E.; Kahana, J.A.; Kral, A.M.; Leander, K.; Lee, L.L.; Malinowski, J.; McAvoy, E.M.; Nahas, D.D.; Robinson, R.G.; Huber, H.E. Identification and characterization of pleckstrinhomology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J., 2005, 385(part2), 399-408.
38. Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(3), 761-764.
39. Zollinger, A.; Stuhmer, T.; Chatterjee, M.; Gattenlohner, S.; Haralambieva, E.; Muller-Hermelink, H-K.; Andrulis, M.; Greiner, A.; Wesemeler, C.; Rath, J.C.; Einsele, H.; Bargou, R,C. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroup: Akt-dependent and Akt-independent multiple myeloma. Blood, 2008, 112(8), 3403-3411.
40. Mahadevan, D.; Powis, G.; Mash, E.A.; George, B.; Gokhale, V.M.; Zhang, S.; Shalalya, K.; Du-Cuny, L.; Berggren, M.; Ali, M.A.; Jana, U.; Ihle, N.; Moses, S.; Franklin, C.; Narayan, S.; Sfirahatti, N.; Meuillet, E.J. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol. Cancer Ther., 2008, 7(9), 2621-2632.
41. Yang, L.; Dan, H.C.; Sun, M.; Liu, Q.; Sun, X-M.; Feldman, R.; Hamilton, A.D.; Polokoff, M.; Nicosia, S.V.; Herlyn, M.; Sebti, S.M.; Cheng, J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res., 2004, 64(13), 4394-4399.
42. Luo, Y.; Shoemaker, A.R.; Liu, X.; Woods, K.W.; Thomas, S.A.; de Jong, R.; Han, E.K.; Li, T.; Stoll, V.S.; Powlas, J.A.; Oleksijew, A.; Mitten, M.J.; Shi, Y.; Guan, R.; McGonigal, T.P.; Klinghofer, V.; Johnson, E.F.; Leverson, J.D.; Bouska, J.J.; Mamo, M.; Smith, R.A.; Gramling,-Evans, E.E.; Zinker, B.A.; Mika, A.K.; Nguyen, P.T.; Oltersdorf, T.; Rosenberg, S,H.; Li, Q.; Giranda, V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther., 2005, 4(6), 977-986.
43. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, J.; Mclauchlan, H.; Klevernic, I.; Arthur, J.S.C.; Aless, D.R.; Cohem, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408(part3), 297-315.
44. Thomas, S.A.; Li, T.; Woods, K.W.; Song, X.; Packard, G.; Fischer, J.P.; Diebold, R.B.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E.F.; Bouska, J.J.; Olson, A.; Guan, R.; Magnone, S.R.; Marsh, K.; Luo, Y.; Rosenberg, S.H.; Giranda, V.L.; Li, Q. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg. Med. Chem. Lett., 2006, 16(14), 3740-3744.
45. Rhodes, N.; Heerding, D.A.; Duckett, D.R.; Eberwein, D.J.; Knick, V.B.; Lansing, T.J.; McConnell, R.T.; Gilmer, T.M.; Zhang, S-Y.; Robell, K.; Kahana, J.A.; Geske, R.S.; Kleymenova, E.V.; Choudhry, A.E.; Lai, Z.; Leber, J.D.; Minthorn, E.A.; Strum, S.L.; Wood, E.R.; Huang, P.S.; Copeland, R.A.; Kumar, R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res., 2008, 68(7), 2366-2374.
46. Mandal, M.; Kim, S.; Younes, M.N.; Jasser, S.A.; El-Naggar, A.K.; Mills, G.B.; Myers, J.N. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer, 2005, 92(10), 1899-1905.
47. Georgakis, G.V.; Li, Y.; Rassidakis, G.Z.; Medeiros, L.J.; Mills, G.B.; Younes, A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol., 2006, 132(4), 503-511.
48. Toral-Barza, L.; Zhang, W.G.; Huang, X.; McDonald, L.A.; Salaski, E.J.; Barbieri, L.R.; Ding, W.D.: Krishnamurthy, G.; Hu, Y.B.; Lucas, J.; Bernan, V.S.; Cai, P.; Levin, J.I; Mansour, T.S.; Gibbons, J.J.; Abraham, R.T.; Yu, K. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol. Cancer Ther., 2007, 6(11), 3028-3038.
49. Chaudhuri, D.; Orsulic, S.; Ashok, B. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol. Cancer Ther., 2007, 6(1), 334-345.
50. Yi, T.; Cho, S.G.; Yi, Z.; Pang, X.; Rodriguez, Aggarwal, B.B.; Liu, M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther., 2008, 7(7), 1789-1796.
51. Chiang, G.G.; Abraham, R.T. Targeting the mTOR signaling network in cancer. TRENDS Mol. Med., 2007, 13(10), 433-442.
52. Huang, J.; Manning, B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J., 2008, 412(part2), 179-190.
53. Sarbassov, dos D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 2006, 22(2), 159-168.
54. Gera, J.F.; Mellinghoff, I.K.; Shi, Y.; Rettig, M.B.; Tran, C.; Hsu, J-H.; Sawyers, C.L.; Lichtenstein, A.K. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem., 2004, 279(4), 2737-2746.
55. Recher, C.; Beyne-Rauzy, O.; Demur, C.; Chicanne, G.; Santos, C.D.; Mas, M.D.; Benzaquen, D.; Laurent, G.; Huguet, F.; Payrastre, B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005, 105(6), 2527-2534.
56. Wanner, K.; Hipp, S.; Oelsner, M.; Ringshausen, I.; Bogner, C.; Peschel, C.; Decker, T. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol., 2006, 134(5), 475-484.
57. Kurmasheva, R.T.; Huang, S.; Houghton, P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer, 2006, 95(8), 955-960.
58. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene, 2006, 25(48), 6436-6446.
59. Mita, M.M.; Mita, A.C.; Chu, Q.S.; Rowinsky, E.K.; Fetterly, G.J.; Goldston, M.; Patnaik, A.; Mathews, L.; Ricart, A.D.; Mays, T.; Knowles, H.; Rivera, V.M.; Kreisberg, J.; Bedrosian, C.L.; Tolcher, W. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol., 2008, 26(3), 361-367.
60. Rizzieri, D.A.; Feldman, E.; DiPersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2008, 14(9), 2756-2762.
61. Law, B.K. Rapamycin: an anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol., 2005, 56(1), 47-60.
62. Ito, D.; Fujimoto, K.; Mori, T.; Kami, K.; Koizumi, M.; Toyoda, E.; Kawaguchi, Y.; Doi, R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer, 2006, 118(9), 2337-2343.
63. Haritunians, T.; Mori, A.; O7Kelly, J.; Luong, Q.T.; Giles, F.J.; Koeffler, H.P. Antiproliferative activity of RAD001 (evelolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 2007, 21(2), 333-339.
64. Bardet, V.; Tamburini, J.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Bouscary, D.; Lacombe, C. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica, 2006, 91(6), 757-764.
65. Tamburini, J.; Chapuis, N.; Bardet, V.; Park, S.; Sujobert, P.; Willems, L.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulinlike growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111(1), 379-382.
66. Park, S.; Chapuis, N.; Bardet, V,; Tamburini, J.; Gallay, N.; Willems, L.; Knight, Z.A.; Shokat, K.M.; Azar, N.; Viguie, F.; Ilfrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; D. Bouscary D. PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22(9), 1698-1706.
67. Mann, K.K.; Colombo, M.; miller, W.H. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol. Cancer Ther., 2008, 7(6), 1680-1687.
68. Ramos, A.M.; Fernandez, C.; Amran, D.; Sancho, P.; de Blas, E.; Aller, P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood, 2005, 105(10), 4013-4020.
69. Yu, C.; Rahmani, M.; Dai, Y.; Conrad, D.; Krystal, G.; Dent, P.; Grant, S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res., 2003, 63(8), 1822-1833.
70. Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S.G.; Dent, P.; Spiegel, S.; Grant, S. Coadminstration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res., 2005, 65(6), 2422-2432.
71. Nyakern, M.; Cappellini, A.; Mantovani, I.; martelli, A.M. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther., 2006, 5(6), 1559-1570.
72. Chiarini, F.; Sole, M.D.; Mongiorgi, S.M.; Gaboardi, G.C.; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008, 22(6), 1106-1116.
73. Fala, F.; Blalock, W.L.; Tazzari, P.L.; Cappellini, A.; Chiarini, F.; Martinelli, G.; Tafuri, A.; McCubrey, J.A.; Cocco, L.; Martelli, A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-]5-(3-methyl-2H-indazol-5-yl) pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. Mol. Pharmacol., 2008, 74(3), 884-895.
74. Levy, D.S.; Kahana, J.A.; Kumar, R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood, 2009, 113(8), 1723-1729.
75. Zeng, Z.; Sarbassov, D.D.; Samudio, I.J.; Yee, K.W.L.; Munsell, M.F.; Jackson, C.E.; Giles, F.J.; Sabatini, D.M.; Andreeff, M.; Konopleva, M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 2007, 109(8), 3509-3512.
76. Teachey, D.T.; Obzut, D.A.; Coopeman, J.; Fang, J.; Carroll, M.; Choi, J.K.; Houghton, P.J.; Brown, V.; Grupp, S.A. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 2006, 107(3), 1149-1155.
77. Doepfner, K.T.; Spertini, O.; Arcaro, A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia, 2007, 21(9), 1921-1930.
78. Loges, S.; Tinnefeld, H.; Metzner, A.; Jucker, M.; Butzal, M.; Bruweleit, M.; Fischer, U.; Draab, E.; Schuch, G.; O'-Farrel, A.M.; Hossfeld, D.K.; Bokemeyer, C.; Fiedler, W. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk. Lymphoma, 2006, 47(12), 2601-2609.
79. Hu, X.F.; Li, J.; Yang, E.; Vandervalk, S.; Xing, P.X. Anti-cript Mab inhibit tumour growth and overcome MDR in a human leukemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br. J. Cancer, 2007, 96(6), 918-927.
80. Klejman, A.; Rushen, L.; Morrione, A.; Slupianek, A.; Skorski, T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene, 2002, 21(38), 5868-5876.
81. Nakanishi, T.; Shiozawa, K.; Hassel, B.A.; Ross, D.D. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABLexpressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood, 2006, 108(2), 678-684.
82. Uddin, S.; Hussain, A.R.; Siraj, A.K.; Manogaran, P.S.; Al-Jomah, N.; Moorji, A.; Atizado, V.; Al-Dayel, F.; Belgaumi, A.; El-Solh, H.; Ezzat, A.; Bavi, P.; Al-Kuraya, K.S. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 2006, 10(13)8, 4178-4186.
83. Uddin, A.; Hussain, A.R.; Al-Hussein, K.A.; Manogaran, P.S.; Wickrema, A.; Gutierrez, M.I.; Bhatia, K.G. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin. Cancer Res., 2005, 11(8), 3102-3108.
84. Rudelius, M.; Pittaluga, S.; Nishizuka, S.; Pharm, T.H.; Fend, F.; Jaffe, E.S.; Quintanilla-Martinez, L.; Raffeld, M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 2006, 108(5), 1668-1676.
85. Dal Col, J.; Zancai, P.; Terrin, L.; Guidogoni, M.; Ponzoni, M.; Paven, A.; Spina, M.; Bergamin, S.; Rizzo, S.; Tirelli, U,; De Rossi, A.; Doglioni, C.; Dolcetti, R. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 2008, 111(10), 5142-5151.
86. Leseux, L.; Hamdi, S.M.; al Saati, T.; Capilla, F.; Recher, C.; Laurent, G.; Bezombes, C. Syk-dependent mTOR activation in follicular lymphoma cells. Blood, 2006, 108(13), 4156-4162.
87. Hipp, S.; Ringshausen, I.; Oelsner, M.; Bogner, C.; Peschel, C.; Decker, T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica, 2005, 90(10), 1433-1434.
88. Sin, S.H.; Roy, D.; Wang, L.; Staudt, M.R.; Fakhari, F.D.; Patel, D.D.; Henry, D.; Harrington, W.J.; Damania, B.A.; Dittmer, D.P. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood, 2007, 109(5), 2165-2173.
89. Vega, F.; Medeiros, L.J.; Leventaki, V.; Atwell, C.; Cho-Vega, J.H.; Tian, L.; Claret, F-X.; Rassidakis, G.Z. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res., 2006, 66(13), 6589-6597.
90. Marzec, M.; Kasprzycka, M.; Liu, X.; El-Salem, M.; Halasa, K.; Raghunath, P.N.; Bucki, R.; Wlodarski, P.; Wasik, M.A. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene, 2007, 26(38), 5606-5614.
91. Querfeld, C.; Rizvi, M.A.; Kuzel, T.M.; Guitart, J.; Rademaker, A.; Sabharwal, S.S.; Krett, N.L.; Rosen, S.T. The selective protein kinase C?? inhibitor enzastaurin induces apoptosis in cutaneous Tcell lymphoma cell lines through the AKT pathway. J. Invest. Dermatol., 2006, 126(7), 1641-1647.
92. Ikezoe, T.; Nishioka, C.; Bandobashi, K.; Yang, Y.; Kuwayama, Y.; Adachi, Y.; Takeuchi, T.; Koeffler, H.P.; Taguchi, H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk. Res., 2007, 31(5), 673-682.
93. Schade, A.E.; Powers, J.J.; Wlodarski, M.W.; Maciejewski, P. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood, 2006, 107(12), 4834-4840.
94. Joen, Y.K.; Park, C.H.; Kim, K.Y.; Li, Y.C.; Kim, J.; Kim, Y.A.; Paik, J.H.; Park, B.K.; Kim, C.W.; Kim, Y.N. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt downregulation. J. Pathol., 2007, 213(2), 170-179.
95. Tu, Y.; Gardner, A.; Lichtenstein, A. The phosphatidylinositol 3-kinase/ AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res., 2000, 60(23), 6763-6770.
96. Hideshima, T,; Nakamura, N.; Chauhan, D.; Anderson, K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 2001, 20(42), 5991-6000.
97. Mitsiades, C.S.; Mitsiades, N.; Poulaki, V.; Schlossman, R,; Akiyama, M.; Chauhan.; D.; Hideshima, T.; Treon, S.P.; Munshi, C.N.; Richardson, P.G.; Anderson, K.C. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 2002, 21(37), 5673-5683.
98. Pene, F.; Claessens, Y-E.; Muller, O.; Viguie, F.; Mayeux, P.; Dreyfus, F.; Lacombe, C.; Bouscary, D. Role of the phosphatidylinositol 3-kinase/ Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 2002, 21(43), 6587-6597.
99. Tai, Y.T.; Podar, K.; Mitsiades, N.; Lin, B.; Mitsiades, C,; Gupta, D.; Akiyama, M.; Catley, L.; Hideshima, T.; Munshi, N.C.; Treon, S.P.; Anderson, K.C. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling. Blood, 2003, 101(7), 2762-2769.
100. Hideshima, T,; Catley, L.; Yasui, H.; Ishitsuka, K.; aje, N.; Mitsiades, C.; podar, K.; Munshi, N.C.; Chauhan, D.; Richardson, P.G.; Anderson, K.D. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107(10), 4053-4062.
101. Hideshima, T.; Catley, L.; Raje, N.; Chauhan, D.; Podar, K.; Mitsiades, C.; Tai, Y.T.; Vallet, S.; Kiziltepe, T.; ocio, E.; Ikeda, H.; Okawa, Y.; Hideshima, H.; Munshi, N.C,; Yasui, H.; Richardson, P.G.; Anderson, K.C. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br, J. Haematol., 2007, 138(6), 783-791.
102. Huston, A.; Leleu, X.; jia, X.; Moreau, A.S.; Ngo, H.T.; Runnels, J.; Anderson, J.; Alsayed, Y.; Roccaro, A.; Vallet, S.; Hatjiharissi, E.; Tai, Y.T.; Sportelli, P.; Munshi, N.; Richardson, P.; Hideshima, T.; Roodman, D.G.; Anderson, K.C.; Ghobrial, I.M. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenviroment. Clin. Cancer Res., 2008, 14(3), 865-874.
103. Leleu, X.; Jia, X.; Runnels, J.; Ngo, H.T.; Moreau, A.S.; Farag, M.; Spencer, J.A.; Pitsillides, C.M.; Hatjiharissi, E.; Roccaro, A.; O'Sullivan, G.; McMillin, D.W.; Moreno, D.; Kiziltepe, T.; Carrasco, R.; Treon, S.P.; Hideshima, T.; Anderson, K.C.; Lin, C.P.; Ghobrial, I.M. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2007, 110(13), 4417-4426.
104. Frost, P.; Moatamed, F.; Hoang, B.; Shi, Y.; Gera, J.; Yan, H.; Frost, P.; Gibbons, J.; Lichtenstein, A. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood, 2004, 104(13), 4181-4187.
105. Frost, P.; Shi, Y.; Hoang, B.; Lichtenstein, A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene, 2007, 26(16), 2255-2262.
106. Raje, N.; Kumar, S.; Hideshima, T.; Ishitsuka, K.; Chauhan, D.; Mitsiades, C.; Podar, K.; La Gouill, S.; Richardson, P.; Munshi, N.C.; Stirling, D.I.; Antin, J.H.; Anderson, K.C. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104(13), 4188-4193.
107. Witzig, T.E.; Geyer, S.M.; Ghobrial, I.; Inwards, D.J.; Fonseca, R.; Kurtin, P.; Ansell, S.M.; Luyun, R.; Flynn, P.J.; Morton, R.F.; Dakhil, S.R.; Gross, H.; Kaufmann, S.H. Phase II trial of singleagent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol., 2005, 23(23), 5347-5356.
108. Yee, K.W.L.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. J. Clin. Cancer Res., 2006, 12(17), 5165-5173.
109. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
110. Yilmaz, O.H.; Valdez, R.; Theisen, B.K.; Guo, W.; Ferguson, D.O.; Wu, H.; Morrison, S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 2006, 441(7092), 475-482.
111. Yamazaki, S.; Iwama, A.; Takayanagi, S.; Morita, Y.; Eto, K.; Ema, H.; Nakauchi, H. Cytokine signals modulated via lipid rafts mimic niche signals and induce hibernation in hematopoietic stem cells. EMBO J., 2006, 25(15), 3515-3523.